Rebleeding occurred in 20/204 (9.8%) bleeds treated with PT ± AF, 9/42 (21.4%) treated with rFVIIa + PT ± AF, 1/78 (1.3%) treated with rFVIIa alone, and 3/69 (4.3%) treated with rFVIIa + AF. This evidence concerns the gene F2 and atrial fibrillation.